1727. Phase 1b Dose-ranging Study Demonstrates Tolerability and Pharmacokinetics (PK) of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease

BACKGROUND: Epetraborole (EBO) — an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activity against nontuberculous mycobacteria — is under clinical development for treatment of MAC lung disease. We conducted a Phase 1b dose-ranging study of EBO tablets in healthy adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckburg, Paul B, Clarke, Dave, Long, Jennifer, Chanda, Sanjay, Krause, Kevin M, Easom, Eric, Talbot, George, Rubino, Christopher M, Molga, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752554/
http://dx.doi.org/10.1093/ofid/ofac492.1357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752554/
http://dx.doi.org/10.1093/ofid/ofac492.1357

Ejemplares similares